29-01-2018
designer491 / iStockphoto.com
Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sanofi, Ablynx, pharmaceutical merger, mergers and acquisitions, blood disorder, nanobody, biotech medicine, caplacizumab, thrombotic thrombocytopenic
Allele Biotech partners with Scientist.com to develop nanoantibodies
05-12-2018
Sanofi in talks to sell generics unit for €1.9bn
19-04-2018
Seattle Genetics to acquire biotech company for $614m
02-02-2018
Celgene reveals plans to acquire Juno for $9bn
23-01-2018
Sanofi to buy Bioverativ for $11.6bn
23-01-2018
